Source:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383151/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383151/
There is
substantial epidemiological evidence pointing to an increased incidence of
breast cancer and morbidity in obese, prediabetic, and diabetic patients.
In vitro studies strongly support metformin, a diabetic medication, in
breast cancer therapy. Although metformin has been heralded as an exciting new
breast cancer treatment, the principal consideration is whether metformin can
be used as a generic treatment for all breast cancer types. I